RecruitingNCT03555578
Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"
Sponsor
Takeda
Enrollment
1,890 participants
Start Date
Nov 2, 2017
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this survey is to evaluate the long-term safety and efficacy of leuprorelin acetate injection kit 11.25 mg in patients with spinal and bulbar muscular atrophy (SBMA) in the routine clinical setting.
Eligibility
Inclusion Criteria1
- All SBMA patients who have been confirmed as receiving the drug
Exclusion Criteria1
- None
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLeuprorelin Acetate
Leuprorelin Acetate Injection Kit
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03555578
Related Trials
Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
NCT049449401 location
Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy
NCT068625965 locations
A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy
NCT061690461 location